A high-throughput multiplexed microfluidic device for COVID-19 serology assays

Rodriguez‐Moncayo, Roberto; Cedillo-Alcantar, Diana F.; Guevara-Pantoja, Pablo E.; Chavez-Pineda, Oriana Gerallin; Hernandez-Ortiz, Jose A.; Amador-Hernandez, Josue U; Rojas‐Velasco, Gustavo; Sánchez‐Muñoz, Fausto; Manzur‐Sandoval, Daniel; Lopez, Luis-David Patiño; May-Arrioja, Daniel A.; Posadas-Sánchez, Rosalinda; Vargas‐Alarcón, Gilberto; García-Cordero, José L.

doi:10.1039/d0lc01068e

Cited by 56 publications

(53 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2c). This sensitivity is comparable to the state-of-the-art micro uidic devices 10,21,22 , whereas the present device is more straightforward to use and has a low infrastructure requirement. Furthermore, in recent studies, the physiologically relevant concentration of this speci c type of anti-spike IgG antibody in recovered COVID-19 infected patients has been shown to be in the range of 9.6 -28 880 nM 23 .…”

Section: Main Textmentioning

confidence: 60%

A nanofluidic device for rapid and multiplexed SARS-CoV-2 serological antibody detection

Mortelmans

Kazazis

Padeste

et al. 2021

Preprint

View full text Add to dashboard Cite

The outbreak of COVID-19 has led to a substantial death toll and has hindered the functioning of modern society, sending the world into a medical and economic crisis1,2. This underlined the importance of point-of-care diagnostics, as well as accurate, cost-effective serological antibody tests as well as point-of-care diagnostics to monitor the viral spread and contain pandemics and endemics. Here, we present a three-dimensional (3D) nanofluidic device for rapid and multiplexed detection of viral antibodies. The device is designed to size-dependently immobilize particles from a multi-particle mixture at predefined positions in nanochannels through capillary forces only, resulting in distinct trapping lines. We show that individual lines can be used as an on-chip fluorescence-linked immunosorbent assay for multiplexed detection of serological immunoglobulin antibodies against viral proteins with high sensitivity. Further device versatility is exhibited by on-bead color multiplexing for simultaneous detection of IgG and IgM antibodies in convalescent human serum and by concurrent detection of anti-spike (SARS-CoV-2) and anti-hemagglutinin (Influenza A) antibodies. The device’s applications can be further extended to detect a plethora of diseases simultaneously in a reliable and straightforward manner.

show abstract

Section: Main Textmentioning

confidence: 60%

A nanofluidic device for rapid and multiplexed SARS-CoV-2 serological antibody detection

Mortelmans

Kazazis

Padeste

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…However, none of the current methods fulfill all the criteria. For SARS-CoV-2 pandemics, currently, sensitive, rapid, high-throughput, and low-cost methods are essentially demanded to detect antibodies and antigens in practical applications including diagnostics, epidemiology, vaccine evaluation, disease understanding, and public health policies at the stage of large-scale outbreak all over the world [ 36 ]. Various immunosensors based on varied matrices have been compared on the basis of their performance and are summarized in Table S4.…”

Section: Discussionmentioning

confidence: 99%

“…However, many approaches [ 43 – 45 ], for instance, ELISA, Fluorescence Immunoassays (FIAs), Lateral Flow Immunoassays (LFIAs), CRISPR Systems, and our microfluidic biochip, were developed for SARS-CoV-2 diagnosis and evaluation. Most of the methods are in phase 1 and 2, but they would still play essential roles in SARS-CoV-2 diagnostics, epidemiology, vaccine evaluation, disease understanding, and public health policies [ 5 , 36 ]. Currently, ELISA, a gold standard of protein assay, is used to validate the accuracy of our microfluidic biochip, and remarkable results were obtained, indicating the potential applications in detection of the real SARS-CoV-2 samples.…”

Section: Discussionmentioning

confidence: 99%

Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip

Wang

Qiu

et al. 2021

Microchim Acta

View full text Add to dashboard Cite

Graphical abstract COVID-19 is now a severe threat to global health. Facing this pandemic, we developed a space-encoding microfluidic biochip for high-throughput, rapid, sensitive, simultaneous quantitative detection of SARS-CoV-2 antigen proteins and IgG/IgM antibodies in serum. The proposed immunoassay biochip integrates the advantages of graphene oxide quantum dots (GOQDs) and microfluidic chip and is capable of conducting multiple SARS-CoV-2 antigens or IgG/IgM antibodies of 60 serum samples simultaneously with only 2 μL sample volume of each patient. Fluorescence intensity of antigens and IgG antibody detection at emission wavelength of ~680 nm was used to quantify the target concentration at excitation wavelength of 632 nm, and emission wavelength of ~519 nm was used during the detection of IgM antibodies at excitation wavelength of 488 nm. The method developed has a large linear quantification detection regime of 5 orders of magnitude, an ultralow detection limit of ~0.3 pg/mL under optimized conditions, and less than 10-min qualitative detection time. The proposed biosensing platform will not only greatly facilitate the rapid diagnosis of COVID-19 patients, but also provide a valuable screening approach for infected patients, medical therapy, and vaccine recipients. Supplementary Information The online version contains supplementary material available at 10.1007/s00604-021-04896-w.

show abstract

“…The first one is a microfluidic platform for the semi-automatic selective detection of IgG and IgM from up to 50 different serum samples in parallel [126]. The device shows several advantages, such as minimal assay reagent consumption, multiple analyte detection, high sensitivity (95%), high specificity (91%) and high-throughput, but it suffers from drawbacks such as cross-reactivity and the long total analysis time.…”

Section: µPads For Covid-19 Detectionmentioning

confidence: 99%

Paper-Based Biosensors: Frontiers in Point-of-Care Detection of COVID-19 Disease

Antiochia

2021

Biosensors

View full text Add to dashboard Cite

This review summarizes the state of the art of paper-based biosensors (PBBs) for coronavirus disease 2019 (COVID-19) detection. Three categories of PBB are currently being been used for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics, namely for viral gene, viral antigen and antibody detection. The characteristics, the analytical performance, the advantages and drawbacks of each type of biosensor are highlighted and compared with traditional methods. It is hoped that this review will be useful for scientists for the development of novel PBB platforms with enhanced performance for helping to contain the COVID-19 outbreak, by allowing early diagnosis at the point of care (POC).

show abstract

A high-throughput multiplexed microfluidic device for COVID-19 serology assays

Abstract: The applications of serology tests to the virus SARS-CoV-2 are diverse, ranging from diagnosing COVID-19, understanding the humoral response to this disease, estimating its prevalence in a population, to modeling...

Cited by 56 publications

References 41 publications

A nanofluidic device for rapid and multiplexed SARS-CoV-2 serological antibody detection

A nanofluidic device for rapid and multiplexed SARS-CoV-2 serological antibody detection

Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip

Paper-Based Biosensors: Frontiers in Point-of-Care Detection of COVID-19 Disease

Contact Info

Product

Resources

About